Procleix Ultrio Elite Assay (FDA Approved and CE Marked)
Single-tube, highly sensitive detection of HIV-1 RNA, HIV-2 RNA, HCV RNA, and HBV DNA in blood and plasma donations.
The Procleix Ultrio Elite assay is CE marked and FDA approved.
Assay Characteristics
Assay chemistry
- Procleix Panther system
- 
                                                                Qualitative, transcription-mediated amplification (TMA) 
Indication
- Procleix Panther system
- 
                                                                Blood screening, source plasma, cadaveric (non-heart-beating) donors 
Collection tube
- Procleix Panther system
- 
                                                                Serum or plasma collected in K2EDTA, K3EDTA, Greiner K2EDTA sep collection tubes, or BD PPT tubes 
Pool sizes
- Procleix Panther system
- 
                                                                IDT-NAT, 4, 8, 16, 96 
Assay kit size
- Procleix Panther system
- 
                                                                1000 or 5000 tests 
Detected virus
- Procleix Panther system
- 
                                                                HIV-1 group M (subtypes A-H, K, CRF01_AE, CRF03_AB), N, O; HIV-2 subtypes A, B; HCV genotypes 1-6 (subtypes 1a, 1b, 2a/c, 2b, 3a, 3b, 3e, 4a, 4b/c, 5a, 6a); HBV genotypes A-H 
| Platform | Procleix Panther system | 
|---|---|
| Assay chemistry | Qualitative, transcription-mediated amplification (TMA) | 
| Indication | Blood screening, source plasma, cadaveric (non-heart-beating) donors | 
| Collection tube | Serum or plasma collected in K2EDTA, K3EDTA, Greiner K2EDTA sep collection tubes, or BD PPT tubes | 
| Pool sizes | IDT-NAT, 4, 8, 16, 96 | 
| Assay kit size | 1000 or 5000 tests | 
| Detected virus | HIV-1 group M (subtypes A-H, K, CRF01_AE, CRF03_AB), N, O; HIV-2 subtypes A, B; HCV genotypes 1-6 (subtypes 1a, 1b, 2a/c, 2b, 3a, 3b, 3e, 4a, 4b/c, 5a, 6a); HBV genotypes A-H | 
Explore other Procleix Assays
Expand your blood screening with a comprehensive NAT assay portfolio.